000			02637nab a2200277 a 4500
003			AR-ReUNN
005			20260702004711.0
008			260701s2021 ag |||||||||||||||||eng
041	0		_aeng
100	1		_aRen, Ke _9197124
245	1	0	_aExosomas en perspectiva: un sustituto potencial de la terapia con células madre
246	1	3	_aExosomes in perspective: a potential surrogate for stem cell therapy
264		1	_c2021
300			_a14 páginas
520			_aExosomes as a unique subtype of small extracellular vesicles (sEVs) have attracted increasing interest in recent years in the fields of mesenchymal stromal cell (MSC) research. Studies have confirmed that exosomes derived from MSCs preserve immunosuppressive phenotype and can mimic therapeutic benefits of their parent cells. This review briefly summarizes most recent findings on the potential of exosomes as an alternative of therapeutic MSCs, focusing on the role of MSCs and their secreted exosomes in regulation of immune cells, preclinical and clinical evidence of therapeutic outcomes of MSC exosomes, and the biodistribution and pharmacokinetic profile of systemically administered exosomes. It is appreciated that exosomes from MSCs of different sources have variable contents including inflammatory mediators, tropic factors, signaling molecules, and nucleic acids (DNA, mRNA, microRNA and long non-coding RNA). Diverse functions of exosomes derived from different sources are expected. More importantly, exosomes isolated in vitro may not mirror that from in vivo, where donor MSCs are exposed to specific disease or injury-related conditions. Simulating in vivo microenvironment by pretreatment of MSCs with relevant chemical mediators may lead to their secretion of therapeutically more efficient exosomes/sEVs. However, we know very little about the key molecules involved and the differences between exosomes released under different conditions. These issues would be of tremendous interest to preclinical research that pursues exosome biology-underlain therapeutic mechanisms of MSCs. Further studies are expected to demonstrate the superiority of MSC-derived exsomes/sEVs as a pharmaceutical entity with regard to efficacy, safety, and practicability.
650		4	_aCelula del Estroma de la Mèdula Osea _9197125
650		4	_aCelulas Estromales Mesenquimales _9197126
650		4	_aVesiculas Extracelulares _9197127
650		4	_aRegulaciòn Inmunològica _9197128
650		4	_aTreg _9197129
650		4	_aDolor _912421
773	0		_tOdontology _x1618-1247 _gv. 107 n. 3 (2019) _w257190
942			_cART
035			_a(ODN)64354
001			265468
999			_c265468 _d265468
040			_aAR-ReUNN _bspa _cAR-ReUNN _eaacr2